 |
6 Products |  |
65 Diseases | | 6 Products |
|
8 Trials |  |
264 News |  |
| «123 |
- |||||||||| ZEMBRACE SymTouch (sumatriptan succinate) / Tonix
New P3 trial: RESTOR: DFN-11 Injection in Episodic Migraine With or Without Aura (clinicaltrials.gov) - Oct 7, 2015
P3, N=266, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Enrollment status: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Sep 17, 2015
P2, N=30, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Enrolling by invitation --> Recruiting
- ||||||| Nayzilam (midazolam intranasal) / UCB
Trial completion: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU (clinicaltrials.gov) - Sep 14, 2015
P3, N=62, Completed, Sponsor: Upsher-Smith Laboratories
Enrolling by invitation --> Recruiting Recruiting --> Completed
- |||| PRX167700 / Sawai Pharma, Roche
Trial completion: An Exploratory Study of PRX167700 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Aug 26, 2015
P2, N=74, Completed, Sponsor: Proximagen Limited
Recruiting --> Completed Active, not recruiting --> Completed
- naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Trial primary completion date: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - Jun 11, 2015
P2, N=9, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> May 2018
- ||||| Nayzilam (midazolam intranasal) / UCB
Enrollment change, Trial primary completion date: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU (clinicaltrials.gov) - Jun 11, 2015
P3, N=62, Recruiting, Sponsor: Upsher-Smith Laboratories
Trial primary completion date: Aug 2015 --> May 2018 N=48 --> 62 | Trial primary completion date: May 2015 --> Oct 2015
- naluzotan (PRX-00023) / National Institutes of Health, Sawai Pharma
Enrollment status, Enrollment change: PRX-00023 Therapy in Localization-Related Epilepsy (clinicaltrials.gov) - May 12, 2015
P2, N=9, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=48 --> 62 | Trial primary completion date: May 2015 --> Oct 2015 Recruiting --> Enrolling by invitation | N=30 --> 9
- |||| Nayzilam (midazolam intranasal) / UCB
Trial primary completion date: ARTEMIS-2: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - May 6, 2015
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories
Recruiting --> Enrolling by invitation | N=30 --> 9 Trial primary completion date: Mar 2015 --> Mar 2016
- |||| Nayzilam (midazolam intranasal) / UCB
Trial primary completion date: ARTEMIS1: Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (clinicaltrials.gov) - Apr 21, 2015
P3, N=165, Recruiting, Sponsor: Upsher-Smith Laboratories
Trial primary completion date: Mar 2015 --> Mar 2016 Trial primary completion date: Mar 2015 --> Sep 2015
- Nayzilam (midazolam intranasal) / UCB
Trial termination: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Apr 21, 2015
P3, N=50, Terminated, Sponsor: Upsher-Smith Laboratories
Recruiting --> Terminated; Study terminated due to slow enrollment. There were no safety concerns.
- ||||| Tosymra (intranasal sumatriptan) / Neurelis, Tonix
Enrollment closed: DFN-02 Open Label Safety Study in Patients With Acute Migraine (clinicaltrials.gov) - Feb 19, 2015
P3, N=150, Active, not recruiting, Sponsor: Dr. Reddy's Laboratories Limited
There were no safety concerns. Recruiting --> Active, not recruiting
- |||| Nayzilam (midazolam intranasal) / UCB
Trial primary completion date: ARTEMIS-2: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Dec 30, 2014
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Mar 2015
- |||| Nayzilam (midazolam intranasal) / UCB
Trial primary completion date: ARTEMIS1: Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (clinicaltrials.gov) - Dec 30, 2014
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories
Trial primary completion date: Sep 2014 --> Mar 2015 Trial primary completion date: Oct 2014 --> Mar 2015
- |||||||||| Tosymra (intranasal sumatriptan) / Neurelis, Tonix
New P3 trial: DFN-02 Open Label Safety Study in Patients With Acute Migraine (clinicaltrials.gov) - Oct 30, 2014
P3, N=150, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- ||| PRX167700 / Sawai Pharma, Roche
Enrollment closed: An Exploratory Study of PRX167700 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Aug 22, 2014
P2, N=74, Active, not recruiting, Sponsor: Proximagen Limited
Trial primary completion date: Oct 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- ||| Nayzilam (midazolam intranasal) / UCB
New P3 trial: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Jun 12, 2014
P3, N=50, Recruiting, Sponsor: Upsher-Smith Laboratories
- | Nayzilam (midazolam intranasal) / UCB
Enrollment open: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU (clinicaltrials.gov) - Dec 2, 2013
P3, N=48, Recruiting, Sponsor: Upsher-Smith Laboratories
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Nayzilam (midazolam intranasal) / UCB
New P3 trial: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU (clinicaltrials.gov) - Dec 1, 2013
P3, N=48, Recruiting, Sponsor: Upsher-Smith Laboratories
- | PRX167700 / Sawai Pharma, Roche
New P2 trial: An Exploratory Study of PRX167700 in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Sep 16, 2013
P2, N=74, Recruiting, Sponsor: Proximagen Limited
- |||||| Nayzilam (midazolam intranasal) / UCB
Enrollment open: ARTEMIS-2: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Oct 29, 2012
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Nayzilam (midazolam intranasal) / UCB
Trial initiation date: ARTEMIS-2: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Jun 11, 2012
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories
Not yet recruiting --> Recruiting Initiation date: Apr 2012 --> Jul 2012
- |||||||||| Nayzilam (midazolam intranasal) / UCB
New P3 trial: ARTEMIS-2: Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters (clinicaltrials.gov) - Feb 6, 2012
P3, N=155, Recruiting, Sponsor: Upsher-Smith Laboratories